ABSTRACT
The objective of this study was to evaluate the effect of essential oils plus dry herbs (PHYTO) and encapsulated sodium butyrate (BUT) supplementation compared with enramycin (ENR), as a growth promoter, on the performance, diarrhoea control and intestinal microbiota in lightly weaned piglets. Two hundred weaned piglets, 20 days old, 4.69 ± 0.56 kg, were submitted during the nursery phase (20 to 69 days of age) to four treatments: control (CTR)-without any additive supplementation; ENR (with 8 ppm of enramycin throughout), BUT (with 2000 ppm between 20 to 34 d, 1500 ppm between 34 to 48 d and 1000 ppm between 48 to 69 d), and PHYTO (150 ppm between 20 to 48 d). At 62 days old, forty piglets (10 replicates per treatment) were slaughtered to perform bacterial identification through 16S rRNA (V3-V4) sequencing of the caecal content. During the second phase of the trial (34 to 48 days), the BUT group showed higher DWG (P = 0.023) and BW (P = 0.039) than the CTR group, and all groups that received additives had better FCR than the CTR group (P = 0.001). In the last phase of the trial (48 to 69 days), the ENR group presented a better FCR (P = 0.054) than the CRT and other groups. In the total period (20 to 69 days), ENR and BUT showed better FCR (P = 0.006) than CRT. Diarrhoea incident data showed differences (P<0.05), favouring the BUT treatment compared to the CTR. Only the Megasphaeraceae and Streptococcaceae families showed differences (p<0.05) in relative abundance between CTR and PHYTO and between CTR and BUT, respectively. Differential abundances of the Megasphaera and Streptococcus genera were observed between CTR and PHYTO and CTR and BUT. Phytogenics and encapsulated sodium butyrate are able and effective for modulating the specific caecal microbiota, improving performance and controlling diarrhoea occurrence.
Subject(s)
Anti-Bacterial Agents , Diet , Animals , Anti-Bacterial Agents/pharmacology , Butyric Acid , Diarrhea/veterinary , RNA, Ribosomal, 16S/genetics , SwineABSTRACT
ABSTRACT: The aim of this study was to evaluate two feed additives, one based on encapsulated sodium butyrate (Adimix® Precision) (AD) and the other, a phytogenic (Apex® 5) (AX), associated or not with an antimicrobial growth promoter (tylosin) during the growth and finishing phases on performance, carcass characteristics and health conditions. A total of 300 barrows and females were distributed in six treatments in a randomized block design with ten replicates. The treatments consisted of a negative control (NC), positive control (PC) (tylosin), AD (encapsulated sodium butyrate), AX (phytogenic), PC+AD (tylosin+encapsulated sodium butyrate), and PC+AX (tylosin+phytogenic). The performance (live weight, daily feed intake, average daily gain and feed conversion) and carcass data (carcass weight, backfat thickness, loin depth, lean meat on the carcass) were submitted to ANOVA plus Tukey's test, and the health conditions (occurrence of diseases, culling, and spontaneous deaths) were analyzed by χ2. Animals of the AD group had the highest average daily gain (ADG) over the evaluation period and the highest live weight at 120, 140, and 164 days of age, in addition to the highest carcass weight compared to NC and PC groups. The AX treatment increased the ADG in growth phase II and the live weight at 120 and 140 days of age in relation to the NC. The PC+AX group had a higher final live weight compared to the NC and PC groups and higher carcass weight in relation to the NC group. There was no difference among treatments for backfat thickness, percentage of lean meat in the carcass, or occurrence of diseases and deaths. The inclusion of encapsulated sodium butyrate (AD treatment) was effective in increasing ADG, final live weight, and carcass weight compared to supplementation with tylosin (PC treatment), as was the inclusion of a phytogenic (AX treatment) on FC compared to the PC.
RESUMO: O objetivo deste estudo foi avaliar dois aditivos alimentares, um a base de butirato de sódio encapsulado (Adimix® Precision) (AD) e outro a base de um fitogênico (Apex® 5) (AX), associados ou não a um antibiótico promotor de crescimento (tilosina), durante as fases de crescimento e terminação, sobre o desempenho, características da carcaça e status de saúde. Foram utilizados 300 suínos machos castrados e fêmeas distribuídos em seis tratamentos em um delineamento em blocos casualizados com dez repetições. Os tratamentos consistiram em um controle negativo (CN), controle positivo (CP) (tilosina), AD (butirato de sódio encapsulado), AX (fitogênico), CP+AD (tilosina+butirato de sódio encapsulado) e CP+AX (tilosina+fitogênico). Os dados de desempenho (peso vivo, consumo diário de ração, ganho de peso médio diário e conversão alimentar) e de carcaça (peso de carcaça, espessura de toucinho, profundidade do lombo e carne magra na carcaça) foram submetidos à ANOVA seguido por teste de Tukey, e os dados de condição de saúde (ocorrência de doenças, animais eutanasiados e mortos espontaneamente) foram analisados pelo teste de χ2. Os animais do grupo AD apresentaram maior ganho de peso diário (GPD) durante o período de avaliação e maior peso vivo aos 120, 140 e 164 dias de idade, além de maior peso de carcaça em comparação aos grupos CN e CP. O tratamento AX aumentou o GPD na fase crescimento II e o peso vivo aos 120 e 140 dias de idade em relação ao CN. O grupo CP+AX apresentou maior peso final em relação aos grupos CN e CP e maior peso de carcaça em relação ao CN. Não houve diferença entre os tratamentos para espessura de toucinho, porcentagem de carne magra na carcaça e ocorrência de doenças e óbitos. A inclusão de butirato de sódio encapsulado (tratamento AD) foi efetiva no aumento de GPD, peso final e peso de carcaça em comparação à suplementação com tilosina (tratamento CP), assim como a inclusão fitogênico (tratamento AX) melhorou a conversão alimentar em comparação ao grupo CP.
